Takeda Pharmaceutical Company Limited TAKP34.SA Stock
Takeda Pharmaceutical Company Limited Price Chart
Takeda Pharmaceutical Company Limited TAKP34.SA Financial and Trading Overview
Takeda Pharmaceutical Company Limited stock price | 68.53 BRL |
Previous Close | 79.25 BRL |
Open | 0 BRL |
Bid | 77.38 BRL x N/A |
Ask | 82.08 BRL x N/A |
Day's Range | 0 - 0 BRL |
52 Week Range | 0 - 92 BRL |
Volume | 0 BRL |
Avg. Volume | 4 BRL |
Market Cap | 245.45B BRL |
Beta (5Y Monthly) | 0.677011 |
PE Ratio (TTM) | 11.257102 |
EPS (TTM) | 3.74 BRL |
Forward Dividend & Yield | 3.49 (4.40%) |
Ex-Dividend Date | March 30, 2023 |
1y Target Est | N/A |
TAKP34.SA Valuation Measures
Enterprise Value | 4.63T BRL |
Trailing P/E | 11.257102 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.060943242 |
Price/Book (mrq) | 0.038776845 |
Enterprise Value/Revenue | 1.15 |
Enterprise Value/EBITDA | 3.785 |
Trading Information
Takeda Pharmaceutical Company Limited Stock Price History
Beta (5Y Monthly) | 0.677011 |
52-Week Change | 16.87% |
S&P500 52-Week Change | 20.43% |
52 Week High | 92 BRL |
52 Week Low | 0 BRL |
50-Day Moving Average | 82.16 BRL |
200-Day Moving Average | 77.94 BRL |
TAKP34.SA Share Statistics
Avg. Volume (3 month) | 4 BRL |
Avg. Daily Volume (10-Days) | 3 BRL |
Shares Outstanding | 1.56B |
Float | 3.07B |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 180 |
Trailing Annual Dividend Yield | 227.12% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.4593 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 7.87% |
Operating Margin (ttm) | 13.87% |
Gross Margin | 69.10% |
EBITDA Margin | 30.37% |
Management Effectiveness
Return on Assets (ttm) | 2.57% |
Return on Equity (ttm) | 5.26% |
Income Statement
Revenue (ttm) | 4.03T BRL |
Revenue Per Share (ttm) | 1297.67 BRL |
Quarterly Revenue Growth (yoy) | 9.50% |
Gross Profit (ttm) | N/A |
EBITDA | 1.22T BRL |
Net Income Avi to Common (ttm) | 317.02B BRL |
Diluted EPS (ttm) | 7.04 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 533.53B BRL |
Total Cash Per Share (mrq) | 171.61 BRL |
Total Debt (mrq) | 4.92T BRL |
Total Debt/Equity (mrq) | 77.37 BRL |
Current Ratio (mrq) | 0.966 |
Book Value Per Share (mrq) | 2043.7455 |
Cash Flow Statement
Operating Cash Flow (ttm) | 977.16B BRL |
Levered Free Cash Flow (ttm) | 468.63B BRL |
Profile of Takeda Pharmaceutical Company Limited
Country | Brazil |
State | N/A |
City | Tokyo |
Address | 1-1, Nihonbashi-Honcho 2-chome |
ZIP | 103-8668 |
Phone | 81 3 3278 2111 |
Website | https://www.takeda.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Q&A For Takeda Pharmaceutical Company Limited Stock
What is a current TAKP34.SA stock price?
Takeda Pharmaceutical Company Limited TAKP34.SA stock price today per share is 68.53 BRL.
How to purchase Takeda Pharmaceutical Company Limited stock?
You can buy TAKP34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Takeda Pharmaceutical Company Limited?
The stock symbol or ticker of Takeda Pharmaceutical Company Limited is TAKP34.SA.
Which industry does the Takeda Pharmaceutical Company Limited company belong to?
The Takeda Pharmaceutical Company Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Takeda Pharmaceutical Company Limited have in circulation?
The max supply of Takeda Pharmaceutical Company Limited shares is 3.16B.
What is Takeda Pharmaceutical Company Limited Price to Earnings Ratio (PE Ratio)?
Takeda Pharmaceutical Company Limited PE Ratio is 18.32352800 now.
What was Takeda Pharmaceutical Company Limited earnings per share over the trailing 12 months (TTM)?
Takeda Pharmaceutical Company Limited EPS is 3.74 BRL over the trailing 12 months.
Which sector does the Takeda Pharmaceutical Company Limited company belong to?
The Takeda Pharmaceutical Company Limited sector is Healthcare.